Mergers & Acquisitions
By The Online Investor Staff, updated Fri., Mar. 29, 6:35 AM
Slide #74. Bristol Myers Squibb — Karuna Therapeutics, Inc.
Acquirer: |
Bristol Myers Squibb (NYSE:BMY) |
Acquiree: |
Karuna Therapeutics, Inc. |
Details: |
Bristol Myers Squibb (NYSE:BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. ("Karuna"). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb ("BMS"). |
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
Bristol-Myers Squibb SEC Filing Email Alerts Service
Preferred: BMYMP
Open the BMY Page at The Online Investor »
Company Name: |
Bristol Myers Squibb Co. |
Stock buyback: |
BMY buyback |
Website: |
www.bms.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding BMY: |
125 |
Total Market Value Held by ETFs: |
$14.89B |
Total Market Capitalization: |
$106.27B |
% of Market Cap. Held by ETFs: |
14.01% |
|
Open the BMY Page at The Online Investor (in a new window) »
|
March 29, 2024 6:35 AM Eastern
Hold (2.30 out of 4)
0th percentile
|
|